Immunome Inc. (IMNM) To Acquire AL102

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPGI
8. RIVN
9. CBOE
10. AGIO

Go back to Immunome Inc. (IMNM) To Acquire AL102

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

February 6, 2024 8:00 AM EST

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile

BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company... More